Change search
ReferencesLink to record
Permanent link

Direct link
Towards Understanding the Roles of Heparan Sulfate Proteoglycans in Alzheimer's Disease
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Neuroscience, Pharmacology.
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Medical Biochemistry and Microbiology.
2014 (English)In: BioMed Research International, ISSN 2314-6133, E-ISSN 2314-6141, 516028- p.Article, review/survey (Refereed) Published
Abstract [en]

Alzheimer's disease (AD) is the most common form of dementia, characterized by progressive loss of memory and cognitive dysfunctions. A central pathological event of AD is accumulation and deposition of cytotoxic amyloid-beta peptide (A beta) in the brain parenchyma. Heparan sulfate proteoglycans (HSPGs) and the side chains heparan sulfate (HS) are found associated with A beta deposits in the brains of AD patients and transgenic animal models of AD. A growing body of evidence from in vitro and in vivo studies suggests functional roles of HSPG/HS in A beta pathogenesis. Although the question of "how and why HSPG/HS is codeposited with A beta?" still remains, it is within reach to understand the mechanisms of the events. Recent progress by immunohistochemical examination with advanced antibodies shed light on molecular structures of HS codeposited with A beta Several recent reports have provided important new insights into the roles of HSPG in A beta pathogenesis. Particularly, experiments on mouse models revealed indispensible functions of HSPG in modulating A beta-associated neuroinflammation and clearance of A beta from the brain. Application of molecules to interfere with the interaction between HS and A beta peptides has demonstrated beneficial effects on AD mouse models. Elucidating the functions of HSPG/HS in A beta deposition and toxicity is leading to further understanding of the complex pathology of AD. The progress is encouraging development of new treatments for AD by targeting HS-A beta interactions.

Place, publisher, year, edition, pages
2014. 516028- p.
National Category
Medical Biotechnology
URN: urn:nbn:se:uu:diva-231495DOI: 10.1155/2014/516028ISI: 000340142600001OAI: diva2:744783
Available from: 2014-09-08 Created: 2014-09-08 Last updated: 2014-09-08Bibliographically approved

Open Access in DiVA

fulltext(1214 kB)104 downloads
File information
File name FULLTEXT01.pdfFile size 1214 kBChecksum SHA-512
Type fulltextMimetype application/pdf

Other links

Publisher's full text

Search in DiVA

By author/editor
Zhang, XiaoLi, Jin-Ping
By organisation
PharmacologyDepartment of Medical Biochemistry and Microbiology
In the same journal
BioMed Research International
Medical Biotechnology

Search outside of DiVA

GoogleGoogle Scholar
Total: 104 downloads
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Altmetric score

Total: 286 hits
ReferencesLink to record
Permanent link

Direct link